Carroll Investors’s Recursion Pharmaceuticals RXRX Stock Holding History

Carroll Investors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.56M	Buy	509,425 +104,489	+26%	+$404K	0.84%	17
2025 Q4	$1.66M	Buy	404,936 +8,235	+2%	+$40.8K	0.79%	17
2025 Q3	$1.94M	Buy	396,701 +11,099	+3%	+$58.3K	0.94%	15
2025 Q2	$1.95M	Buy	385,602 +44,271	+13%	+$217K	1.03%	16
2025 Q1	$1.81M	Buy	341,331 +94,346	+38%	+$688K	1.2%	14
2024 Q4	$1.67M	Buy	246,985 +84,245	+52%	+$566K	0.94%	15
2024 Q3	$1.08M	Buy	162,740 +81,974	+101%	+$588K	0.71%	17
2024 Q2	$606K	Buy	80,766 +66,967	+485%	+$584K	0.42%	17
2024 Q1	$138K	Buy	+13,799	New	+$154K	0.1%	23

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Carroll Investors's RXRX Position: Q1 2026 in Review

Carroll Investors increased its Recursion Pharmaceuticals (RXRX) stake by 26% in Q1 2026, buying an estimated $404K and bringing the position to 509,425 shares worth $1.56M. The position accounts for 0.84% of the portfolio, ranked #17.

Carroll Investors first reported a position in RXRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.95M in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Carroll Investors held 509,425 shares of Recursion Pharmaceuticals worth $1.56M as of Q1 2026.
Carroll Investors bought 104,489 Recursion Pharmaceuticals shares in Q1 2026, an estimated $404K.
Recursion Pharmaceuticals made up 0.84% of Carroll Investors's portfolio in Q1 2026, its #17 holding.
Carroll Investors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Carroll Investors's Recursion Pharmaceuticals position peaked at $1.95M in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Carroll Investors's 13F filing for Q1 2026, filed 15 May 2026.